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bjectives The aim of this study was to examine outcomes related to the use of the Endeavor zo-
arolimus-eluting stent (ZES) (Medtronic CardioVascular, Santa Rosa, California) compared with the
AXUS paclitaxel-eluting stent (PES) (Boston Scientiﬁc Corp., Natick, Massachusetts) in the 477 pa-
ients with diabetes mellitus (DM) enrolled in the randomized ENDEAVOR IV (Randomized Compari-
on of Zotarolimus- and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease) trial.
ackground Percutaneous coronary intervention (PCI) in diabetic patients is associated with in-
reased rates of restenosis-related end points compared with PCI in nondiabetic patients. Although
ES has been associated with similar clinical efﬁcacy compared with PES in the overall trial popula-
ion of the ENDEAVOR IV trial, whether these results are maintained in the higher-risk restenosis
ubgroup of patients with DM has not been determined.
ethods Clinical and angiographic outcomes were compared according to randomized treatment
ssignment to either ZES or PES.
esults Baseline characteristics were similar among ZES (n  241) and PES (n  236) diabetic patients,
ith slightly longer lesion lengths in PES-treated patients (12.9 mm vs. 14.0 mm, p  0.041). Among the
6 DM patients assigned to routine angiographic follow-up (18% of the overall DM cohort), in-stent per-
ent diameter stenosis at 8 months was greater among ZES-treated patients (32.9 vs. 21.1, p  0.023),
ith a trend toward higher in-stent late loss. One-year clinical outcomes were similar among DM pa-
ients treated with either ZES or PES (target vessel failure: 8.6% vs. 10.8%, p  0.53; target lesion revascu-
arization: 6.9% vs. 5.8%, p  0.70; target vessel revascularization: 8.6% vs. 9.4%, p  0.87). There were
o signiﬁcant interactions between DM status and stent type with respect to the outcomes measured,
nd the relative efﬁcacy/safety of ZES and PES were similar among insulin- and noninsulin-requiring
ubgroups.
onclusions One-year clinical outcomes were similar among DM patients treated with ZES and PES
n the ENDEAVOR IV trial. These ﬁndings parallel the overall trial results, which demonstrated similar
fﬁcacy and safety of ZES and PES for single de novo coronary lesions. (J Am Coll Cardiol Intv
009;2:967–76) © 2009 by the American College of Cardiology Foundation
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968lthough bare-metal stents (BMS) have been demonstrated to
mprove acute outcomes and reduce rates of restenosis com-
ared with balloon angioplasty alone, a significant proportion
f patients treated with BMS experience both angiographic
nd clinical restenosis, leading to repeat revascularization pro-
edures. Patients with diabetes mellitus (DM) are at a partic-
larly greater risk for restenosis and repeat revascularization
rocedures (1) and are also at greater risk for other adverse
linical outcomes, including stent thrombosis (2), myocardial
nfarction (MI), and death (1,3).
Drug-eluting stents (DES) have been shown to significantly
educe the rates of clinical restenosis compared with BMS,
ith similar effects observed in patients with and without DM
(4–11). A newer DES recently
approved in the U.S., the En-
deavor zotarolimus-eluting stent
(ZES) (Medtronic CardioVascu-
lar, Santa Rosa, California), has
been demonstrated in a blinded
randomized trial to reduce angio-
graphic and clinical restenosis
compared with the same control
BMS (12). Despite higher in-
stent late loss, the ZES has been
associated with similar clinical
outcomes compared with the
TAXUS paclitaxel-eluting stent
(PES) (Boston Scientific Corpo-
ration, Natick, Massachusetts) in
the randomized ENDEAVOR
IV (Randomized Comparison of
Zotarolimus- and Paclitaxel-
Eluting Stents in Patients with
Coronary Artery Disease) trial
(13). Because restenosis can be
more aggressive in patients with
DM, it is important to character-
ize whether these results are
maintained in this higher-risk
subgroup of patients undergoing
percutaneous coronary interven-
ion (PCI) with ZES. We therefore sought to examine
utcomes in the ENDEAVOR IV trial related to the random-
zed use of ZES compared with PES and stratified by diabetic
tatus.
ethods
tudy population. The ENDEAVOR IV trial was a pro-
pective, multicenter, single-blind, randomized, controlled
linical trial that compared clinical and angiographic out-
omes between patients randomized to either ZES or PES.
onsecutive adult patients with clinical evidence of isch-
bbreviations
nd Acronyms
RC  Academic Research
onsortium
MS  bare-metal stent
M  diabetes mellitus
DDM  insulin-dependent
iabetes mellitus
ACE  major adverse
ardiac events
LD  minimum lumen
iameter
IDDM  noninsulin-
ependent diabetes mellitus
CI  percutaneous
oronary intervention
ES  paclitaxel-eluting
tent
CA  quantitative coronary
ngiography
LR  target lesion
evascularization
VR  target vessel
evascularization
VF  target vessel failure
ES  zotarolimus-eluting
tentmic coronary disease or a positive functional study were bnrolled at 80 centers in the U.S. Key clinical exclusion
riteria included recent acute MI, another planned PCI
ithin the next 30 days or previous PCI in the target vessel
ithin the previous 9 months, recent stroke or transient
schemic attack, left ventricular ejection fraction 30%, and
ontraindication to dual anti-platelet therapy (aspirin and a
hienopyridine).
Angiographic requirements were the presence of a single
e novo native coronary lesion with a diameter stenosis
DS) at least 50% but 100% by visual estimate, reference
essel diameter 2.5 mm and 3.5 mm, and lesion length
27 mm. A target vessel with evidence of thrombus or
xcessive tortuosity or a target lesion that was in an ostial
ocation or with severe calcification or at a bifurcation
nvolving a side branch 2.0 mm diameter were excluded.
atients with unprotected left main coronary disease were
lso excluded.
After confirmation of eligibility criteria, patients were
tratified by diabetic status and clinical site and were
ubsequently randomized to receive either the ZES or the
ES. Diabetes was defined as treatment for DM with
nsulin, oral antidiabetic agents, or a modified diet.
nd points and deﬁnitions. Study end points were assessed
rospectively and were adjudicated by an independent
linical events committee. The primary end point of the
urrent analysis was the rate of target vessel failure (TVF) (a
omposite of cardiac death, MI, or clinically-driven target
essel revascularization [TVR] of the treated vessel), the
ame end point as for the overall ENDEAVOR IV trial
assessed at 12 months for this analysis). Secondary end
oints included target lesion revascularization (TLR) and
VR. Additional end points were assessed to evaluate stent
afety, including death (all cause, cardiac, noncardiac), MI (all,
-wave, non–Q-wave), composite death or MI, major adverse
ardiac events (MACE; a composite of death, Q-wave MI,
on–Q-wave MI, and target site revascularization), and stent
hrombosis as assessed by the Academic Research Consortium
ARC)definitions(14).Additionally,protocol-mandatedquan-
itative coronary angiography (QCA) was performed at 8
onths in a consecutive series of study patients and
nalyzed by an independent angiographic core laboratory
Brigham and Women’s Hospital, Boston, Massachusetts).
tatistical analysis. Of the original study population of
,548 patients (ZES  773; PES  775), 477 (30.8%) had
iabetes (ZES 241; PES 236). Overall, 18% of patients
n the trial underwent protocol-mandated angiographic
ollow-up (86 diabetic patients, 193 nondiabetic patients).
he primary comparison in the present analysis was be-
ween the randomized treatment arms (ZES and PES)
mong diabetic and nondiabetic patients. Further analyses
ere conducted to assess differences between stent types
mong the subgroups of patients with insulin-dependent
iabetes mellitus (IDDM) and noninsulin-dependent dia-
etes mellitus (NIDDM).
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969Categorical variables were compared with the chi-
quare or Fisher exact test, as appropriate. Continuous
ariables are presented as means with SD and were
ompared with unpaired t tests. Time-to-event data are
eported and displayed as Kaplan-Meier estimates, with
omparisons between groups by the log-rank test. All
nalyses are by intention-to-treat, with all patients ran-
omized to each study stent included. First-order tests of
nteraction terms for primary end points were conducted
ccording to diabetic status (vs. nondiabetic status). Data
ollection, clinical event adjudication, and analysis were per-
ormed at the Harvard Clinical Research Institute (Boston,
assachusetts).
esults
aseline and angiographic characteristics. Compared with
atients without DM, patients with DM were more likely to
e women and more frequently had coexisting cardiovascu-
ar risk factors including a history of smoking, hypertension,
nd hyperlipidemia. The baseline demographic and clinical
haracteristics of the randomized ZES- and PES-treated
roups were well-matched in patients with and without DM
Table 1), consistent with the study stratification by diabetic
tatus, although there was a slightly higher prevalence of
yperlipidemia in diabetic persons randomized to PES.
Table 1. Baseline Demographic Data and Clinical Characteristics
DM
ZES (n  241) PES (
Age (yrs), mean  SD (n) 64.24  11.08 (241) 63.84 
Male 59.8% (144/241) 61.0%
History of smoking 54.4% (129/237) 53.8%
Prior percutaneous coronary revascularization 32.8% (79/241) 32.6%
Hyperlipidemia requiring treatment 83.8% (202/241) 90.3%
Hypertension requiring treatment 90.5% (218/241) 90.7%
Medications
Beta-blockers 66.8% (161/241) 77.1%
ACE inhibitors 77.2% (186/241) 77.5%
Medications for diabetes 88.4% (213/241) 90.3%
Statins 83.0% (200/241) 85.2%
Prior MI 23.0% (54/235) 24.0%
Prior CABG 15.8% (38/241) 11.4%
Clinical presentation
Stable 43.9% (79/180) 51.1%
Unstable 53.3% (96/180) 47.2%
MI 2.8% (5/180) 1.7%
Number of diseased vessels
Single 48.5% (117/241) 51.3%
Double 32.8% (79/241) 28.0%
Triple 18.7% (45/241) 20.8%
Ejection fraction, mean  SD (n) 57.21  10.40 (239) 56.93 ACE angiotensin-converting enzyme; CABG coronary artery bypass graft; DM diabetes mellitus; MIeriprocedural glycoprotein IIb/IIIa inhibitors were used in
similar proportion of ZES- and PES-treated patients
23.7% vs. 25.4%, p  0.653).
Patients with DM had smaller reference vessel diam-
ters compared with patients without DM (2.67 mm vs.
.74 mm, p  0.007). Baseline lesion characteristics were
imilar between ZES and PES among both DM and
on-DM patients (Tables 2 and 3), except for slightly
onger treated lesions among PES-treated patients with
M (14.0 mm vs. 12.9 mm, p  0.041), resulting in
ore discrete lesions treated in ZES patients with DM,
lthough total stent length was similar in patients with
M (20.5 mm for ZES vs. 21.2 mm for PES, p  0.28).
ther baseline lesion characteristics, including lesion
ocation, presence of thrombus, and Thrombolysis In
yocardial Infarction flow, were similar among DM and
on-DM patients treated with ZES and PES. Post-
rocedural QCA of lesions treated with ZES and PES
as also similar in the DM and non-DM patient groups
Table 3).
-month angiography. A total of 86 patients with DM
nderwent mandatory angiographic follow-up at 8
onths (Table 4). Compared with patients without DM,
atients with DM had smaller reference vessel diameters,
maller minimum lumen diameters (MLD), and greater
No DM
36) p Value ZES (n  532) PES (n  539) p Value
236) 0.679 63.17  11.10 (532) 63.43  11.45 (539) 0.711
36) 0.780 70.1% (373/532) 71.8% (387/539) 0.546
34) 0.926 66.3% (350/528) 63.3% (336/531) 0.335
6) 1.000 26.1% (139/532) 28.2% (152/539) 0.451
36) 0.041 80.3% (427/532) 82.4% (444/539) 0.389
36) 1.000 74.4% (396/532) 79.0% (426/539) 0.083
36) 0.014 70.5% (375/532) 69.0% (372/539) 0.642
36) 1.000 52.3% (278/532) 54.5% (294/539) 0.463
36) 0.555 9.0% (48/532) 12.4% (67/539) 0.076
36) 0.534 83.5% (444/532) 82.6% (445/539) 0.745
3) 0.828 20.2% (107/529) 22.8% (120/526) 0.330
6) 0.183 7.1% (38/532) 7.1% (38/539) 1.000
8) 0.345 46.3% (202/436) 46.6% (201/431) 0.878
8) 50.9% (222/436) 51.0% (220/431)
) 2.8% (12/436) 2.3% (10/431)
36) 0.814 57.8% (307/531) 59.9% (322/538) 0.528
6) 26.7% (142/531) 25.3% (136/538)
6) 15.4% (82/531) 14.9% (80/538)
(231) 0.768 57.34  9.70 (521) 57.70  10.29 (522) 0.553n  2
9.87 (
(144/2
(126/2
(77/23
(213/2
(214/2
(182/2
(183/2
(213/2
(201/2
(56/23
(27/23
(91/17
(84/17
(3/178
(121/2
(66/23
(49/23
10.34myocardial infarction; PES paclitaxel-eluting stent(s); ZES zotarolimus-eluting stent(s).
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970ean late loss at 8 months when pooling both the ZES
nd PES stent arms.
At follow-up, compared with DM patients treated with a
ES, DM patients receiving a ZES had smaller in-stent
LD (1.70 mm vs. 2.01 mm, p  0.037) and greater
n-stent percent diameter stenosis (32.9 mm vs. 21.1 mm,
Table 2. Baseline Lesion Characteristics
DM
ZES (n  241) PES (n  236)
Vessel location
LAD 40.0% (96/240) 39.0% (92/236)
LCX 30.0% (72/240) 28.0% (66/236)
RCA 30.0% (72/240) 33.1% (78/236)
Lesion description
Discrete (10 mm) 34.7% (83/239) 28.4% (67/236)
Tubular (10–19.9 mm) 56.1% (134/239) 54.7% (129/236)
Diffuse (20 mm) 9.2% (22/239) 16.9% (40/236)
Thrombus 1.3% (3/240) 0.8% (2/236)
TIMI ﬂow grade
1 0.4% (1/240) 0.8% (2/236)
2 3.3% (8/240) 3.4% (8/236)
3 96.3% (231/240) 95.8% (226/236)
Modiﬁed ACC/AHA
A 8.3% (20/240) 9.3% (22/236)
B1 21.7% (52/240) 21.6% (51/236)
B2 49.6% (119/240) 39.0% (92/236)
C 20.4% (49/240) 30.1% (71/236)
ACC/AHA American College of Cardiology/American Heart Association; LAD left anterior desc
Myocardial Infarction; other abbreviations as in Table 1.
Table 3. Baseline Pre- and Post-Procedural QCA
DM
ZES (n  241) PES (n  23
Pre-procedure
Lesion length (mm) 12.88 5.58 (239) 14.00 6.38 (2
Reference vessel diameter (mm) 2.68 0.48 (240) 2.66 0.47 (2
MLD (mm) 0.95 0.40 (240) 0.94 0.43 (2
% stenosis 64.69 12.90 (240) 65.15 13.47 (
Post-procedure
Reference vessel diameter (mm) 2.72 0.49 (240) 2.71 0.48 (2
In-segment MLD (mm) 2.17 0.48 (240) 2.14 0.51 (2
In-segment % stenosis 20.47 9.64 (240) 21.33 12.79 (
In-stent MLD (mm) 2.55 0.42 (238) 2.58 0.48 (2
In-stent % stenosis 5.58 10.17 (238) 4.47 12.20 (
Proximal edge MLD (mm) 2.66 0.55 (230) 2.68 0.56 (2
Proximal edge % stenosis 2.61 11.15 (230) 1.47 11.21 (
Distal edge MLD (mm) 2.31 0.54 (238) 2.32 0.52 (2
Distal edge % stenosis 15.22 11.59 (238) 14.36 11.58 (
All data are presented as mean SD and include the number of patients with available data.MLDminimum lumen diameter; QCA quantitative coronary angiography; other abbreviations as in 0.023), with a trend toward higher in-stent late loss
0.81 mm vs. 0.56 mm, p 0.073). The rate of in-stent and
segment binary angiographic restenosis was correspond-
ngly higher among ZES-treated patients, although this did
ot achieve statistical significance (in-stent: 25.0% vs.
6.7%, p  0.43; in-segment: 27.3% vs. 23.8%, p  0.81).
No DM
p Value ZES (n  532) PES (n  539) p Value
0.759 43.2% (230/532) 42.6% (229/538) 0.945
25.6% (136/532) 25.3% (136/538)
31.2% (166/532) 32.2% (173/538)
0.022 29.7% (158/532) 30.9% (166/537) 0.991
57.3% (305/532) 54.6% (293/537)
13.0% (69/532) 14.5% (78/537)
1.000 1.7% (9/532) 1.3% (7/538) 0.625
0.780 0.4% (2/531) 0.6% (3/538) 0.962
6.0% (32/531) 5.8% (31/538)
93.6% (497/531) 93.7% (504/538)
0.244 6.0% (32/532) 5.4% (29/538) 0.757
24.6% (131/532) 22.9% (123/538)
41.2% (219/532) 44.6% (240/538)
28.2% (150/532) 27.1% (146/538)
coronary artery; LCX left circumflex artery; RCA right coronary artery; TIMI Thrombolysis In
No DM
p Value ZES (n  532) PES (n  539) p Value
0.041 13.65 5.69 (532) 13.71 5.96 (537) 0.880
0.670 2.76 0.47 (532) 2.72 0.46 (538) 0.195
0.735 0.96 0.41 (532) 0.93 0.39 (538) 0.129
0.700 64.89 13.48 (532) 65.91 12.93 (538) 0.207
0.711 2.82 0.46 (530) 2.79 0.46 (537) 0.222
0.467 2.25 0.46 (530) 2.21 0.49 (537) 0.271
0.408 20.46 9.50 (530) 20.81 10.31 (537) 0.575
0.558 2.65 0.43 (525) 2.63 0.43 (531) 0.364
0.283 5.46 9.35 (525) 5.25 9.65 (531) 0.725
0.676 2.76 0.58 (500) 2.76 0.56 (504) 0.881
0.280 2.36 12.11 (500) 0.90 11.89 (504) 0.054
0.858 2.39 0.53 (520) 2.36 0.54 (527) 0.330
0.423 15.43 11.61 (520) 15.93 11.35 (527) 0.486ending6)
36)
36)
36)
236)
35)
35)
235)
32)
232)
24)
224)
31)
231)Table 1.
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971In patients without DM, ZES-treated patients had
maller in-stent MLD, greater in-stent percent diameter
tenosis, and higher in-stent late loss at follow-up com-
ared with PES-treated patients (0.61 mm vs. 0.35 mm,
 0.001), similar to the findings in patients with DM.
he rate of in-stent and in-segment binary angiographic
estenosis in patients without DM was numerically
igher among ZES-treated patients but did not achieve
tatistical significance (in-stent: 8.1% vs. 2.2%, p  0.10;
n-segment: 10.0% vs. 4.3%, p  0.17).
linical end points. Overall rates of TVF at 1 year were
imilar among DM and non-DM patients when pooled
cross ZES and PES stent types (Table 5). Compared with
atients without DM, patients with DM had higher rates of
LR (6.4% vs. 2.8%, p  0.002) and TVR (9.0% vs. 5.4%,
 0.012) but slightly lower rates of MI at 1 year (0.9% vs.
.6%, p  0.030).
There were no significant differences in the rates of TVF
or ZES- and PES-treated patients, either in patients with
M (8.6% vs. 10.8%, p  0.53) or without DM (7.4% vs.
.9%, p  0.43) (Table 5, Fig. 1). Similarly, at 1 year, there
ere no differences between DES types in the rates of TLR
r TVR in either DM or non-DM patients (Table 5, Fig. 2).
verall MACE was similar among ZES- and PES-treated
atients in DM patients (6.9% vs. 7.2%, p  0.99) and
on-DM patients (6.4% vs. 6.4%, p  1.0), and there were
o differences in any of the individual MACE components
hen compared by DES type in either the DM or non-DM
ohorts. The rate of ARC-defined stent thrombosis was low
n patients with and without DM, with no significant
Table 4. Angiographic Follow-Up at 8 Months
DM
ZES (n  44) PES (n  42)
Reference vessel diameter (mm) 2.55 0.46 (44) 2.54 0.42 (42)
In-segment MLD (mm) 1.60 0.55 (44) 1.73 0.67 (42)
In-segment % stenosis 36.91 19.86 (44) 32.75 21.23 (42
In-stent MLD (mm) 1.70 0.62 (44) 2.01 0.73 (42)
In-stent % stenosis 32.88 22.43 (44) 21.13 24.62 (42
Proximal edge MLD (mm) 2.36 0.55 (42) 2.27 0.80 (42)
Proximal edge % stenosis 6.48 15.54 (42) 11.83 24.66 (42
Distal edge MLD (mm) 2.03 0.56 (44) 2.11 0.54 (42)
Distal edge % stenosis 20.09 16.70 (44) 17.38 15.04 (42
Binary restenosis
In-segment 27.3% (12/44) 23.8% (10/42)
In-stent 25.0% (11/44) 16.7% (7/42)
Proximal edge 4.8% (2/42) 9.5% (4/42)
Distal edge 2.3% (1/44) 2.4% (1/42)
In-segment late loss (mm) 0.46 0.55 (44) 0.38 0.58 (42)
In-stent late loss (mm) 0.81 0.58 (44) 0.56 0.66 (42)
All data are presented as mean SD and include the number of patients with available data.
Abbreviations as in Tables 1 and 3.ifferences between ZES and PES-treated patients in either iohort. There were no significant interactions for the effect
f ZES versus PES on the end points of TVF, TLR, TVR,
nd MACE by DM status.
utcomes in IDDM and NIDDM patients. The baseline de-
ographic, lesion, and procedural characteristics of patients
andomized to ZES and PES implantation were largely
imilar among patients with either IDDM (n  144) or
IDDM (n  333). There was a greater prevalence of a
amily history of coronary artery disease in IDDM patients
reated with ZES and a lesser prevalence of hyperlipidemia
n NIDDM patients treated with ZES. Baseline QCA
emonstrated similar pre- and post-procedural lesion char-
cteristics for patients treated with ZES and PES in both
DDM and NIDDM patient groups (all p values 0.05,
ata not shown).
Patients with IDDM and NIDDM had angiographic
ollow-up and outcomes consistent with the broader DM
ohort, with no evidence of a differential effect of
nsulin-requiring status. Of the 27 patients with IDDM
ndergoing mandatory 8-month angiography, ZES-
reated patients trended toward smaller in-stent MLD
1.84 mm vs. 2.19 mm, p  0.19), greater in-stent
ercent diameter stenosis (30.7% vs. 13.7%, p  0.05),
nd higher in-stent late loss (0.77 mm vs. 0.41 mm, p 
.21). Of the 59 NIDDM patients, ZES-treated patients
rended toward smaller in-stent MLD (1.63 mm vs. 1.94
m, p  0.09), greater in-stent percent diameter stenosis
34.0% vs. 24.1%, p  0.13), and higher in-stent late loss
0.83 vs. 0.63 mm, p  0.19).
The type of diabetes, defined by insulin use, did not
No DM
p Value ZES (n  100) PES (n  93) p Value
0.953 2.70 0.47 (100) 2.74 0.45 (93) 0.530
0.298 1.89 0.54 (100) 2.09 0.47 (93) 0.006
0.351 30.25 15.29 (100) 23.83 11.18 (93) 0.001
0.037 2.06 0.58 (99) 2.36 0.52 (93) .001
0.023 23.53 17.80 (99) 13.82 13.58 (93) .001
0.542 2.48 0.61 (97) 2.61 0.62 (91) 0.181
0.239 7.99 16.41 (97) 4.93 15.15 (91) 0.186
0.501 2.24 0.46 (99) 2.30 0.51 (93) 0.413
0.431 16.81 10.19 (99) 16.58 10.65 (93) 0.879
0.807 10.0% (10/100) 4.3% (4/93) 0.168
0.430 8.1% (8/99) 2.2% (2/93) 0.102
0.676 3.1% (3/97) 1.1% (1/91) 0.622
1.000 0% (0/99) 0% (0/93)
0.526 0.31 0.42 (99) 0.16 0.35 (93) 0.009
0.073 0.61 0.44 (98) 0.35 0.39 (93) .001)
)
)
)mpact clinical end points for ZES or PES differently
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972rom the overall study population (Table 6). The rate of
VF was no different among ZES- and PES-treated
atients with either IDDM (3.8% vs. 8.5%, p  0.29) or
IDDM (11.0% vs. 11.6%, p  1.0). Similarly, the rates
f TLR and TVR were comparable with both stents in
oth the IDDM and NIDDM cohorts. The overall
ACE rate was similar with ZES and PES in the
DDM (3.8% vs. 5.1%, p  1.0) and NIDDM (8.4% vs.
.9%, p  1.0) cohorts. There were no differences in
A
Figure 1. TVF
Kaplan-Meier estimates representing the 1-year incidence of the primary study
Table 5. Outcomes and Major Adverse Events at 1 Year
DM
ZES (n  241) PES (n 
MACE (death, MI, emergent CABG, TLR) 6.9% (16/233) 7.2% (16/
Death 0.0% (0/233) 0.9% (2/2
Cardiac death 0.0% (0/233) 0.9% (2/2
MI (Q-wave or non–Q-wave) 0.9% (2/233) 0.9% (2/2
Q-wave MI 0.0% (0/233) 0.0% (0/2
Non–Q-wave MI 0.9% (2/233) 0.9% (2/2
Emergent CABG 0.0% (0/233) 0.4% (1/2
TLR 6.9% (16/233) 5.8% (13/
TL-CABG 0.4% (1/233) 1.8% (4/2
TL-PTCA 6.4% (15/233) 4.0% (9/2
TVR not involving the target lesion 2.6% (6/233) 4.5% (10/
TVR/non–TL-CABG 0.0% (0/233) 1.3% (3/2
TVR/non–TL-PTCA 2.6% (6/233) 3.6% (8/2
TVR 8.6% (20/233) 9.4% (21/
Target vessel failure 8.6% (20/233) 10.8% (24/
Stent thrombosis (ARC)
Deﬁnite 0.9% (2/233) 0.4% (1/2
Probable 0.4% (1/233) 0% (0/2
Deﬁnite/probable 1.3% (3/233) 0.4% (1/2
ARC  Academic Research Consortium; MACE  major adverse cardiac event; PTCA  percut
revascularization; other abbreviations as in Table 1.taxel-eluting stent (PES)-treated patients with diabetes mellitus (A) and without diabndividual MACE components or ARC-defined stent
hrombosis by stent type in patients with either IDDM or
IDDM.
iscussion
n the ENDEAVOR IV trial, treatment of single de novo
oronary lesions with either ZES or PES was associated
ith comparable clinical outcomes at 1 year (13). In this
oint, target vessel failure (TVF) for zotarolimus-eluting stent (ZES)- and pacli-
No DM
p Value ZES (n  532) PES (n  539) p Value
1.000 6.4% (33/516) 6.4% (33/518) 1.000
0.239 1.6% (8/516) 1.2% (6/518) 0.604
0.239 0.8% (4/516) 0.4% (2/518) 0.451
1.000 1.9% (10/516) 3.3% (17/518) 0.242
0.4% (2/516) 0.2% (1/518) 0.624
1.000 1.6% (8/516) 3.1% (16/518) 0.147
0.489 0% (0/516) 0.2% (1/518) 1.000
0.704 3.5% (18/516) 2.1% (11/518) 0.193
0.207 0.6% (3/516) 0.4% (2/518) 0.686
0.297 3.1% (16/516) 1.7% (9/518) 0.163
0.315 2.5% (13/516) 4.1% (21/518) 0.222
0.116 0.6% (3/516) 0.8% (4/518) 1.000
0.595 2.1% (11/516) 3.3% (17/518) 0.338
0.870 5.2% (27/516) 5.6% (29/518) 0.891
0.526 7.4% (38/516) 8.9% (46/518) 0.426
1.000 0.6% (3/516) 0% (0/518) 0.124
1.000 0.2% (1/516) 0% (0/518) 0.499
0.624 0.8% (4/516) 0% (0/518) 0.062
transluminal coronary angioplasty; TLR  target lesion revascularization; TVR  target vesselB
end p236)
223)
23)
23)
23)
23)
23)
23)
223)
23)
23)
223)
23)
23)
223)
223)
23)
23)
23)
aneousetes mellitus (B). Error bars represent 95% conﬁdence intervals.
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973ubset analysis of the ENDEAVOR IV trial, we sought
o further characterize trial outcomes in the high-
estenosis-risk subgroup of patients with DM, represent-
ng 30.8% of the overall study population. The principal
ndings of this subgroup analysis are: 1) despite a relative
ncrease in rates of QCA-based restenosis end points in
he cohort of patients undergoing protocol-mandated
ollow-up angiography, ZES and PES had virtually
dentical rates of clinical restenosis end points in patients
A
Figure 2. TLR
Kaplan-Meier estimates representing the 1-year incidence of target lesion reva
without diabetes mellitus (B). Error bars represent 95% conﬁdence intervals. A
Table 6. Outcomes and Major Adverse Events at 1 Year by IDDM Status
IDDM
ZES (n  80) PES (n 
MACE (death, MI, emergent CABG, TLR) 3.8% (3/78) 5.1% (3/5
Death 0.0% (0/78) 0.0% (0/5
Cardiac death 0.0% (0/78) 0.0% (0/5
MI (Q-wave or non–Q-wave) 1.3% (1/78) 0.0% (0/5
Q-wave MI 0.0% (0/78) 0.0% (0/5
Non–Q-wave MI 1.3% (1/78) 0.0% (0/5
Emergent CABG 0.0% (0/78) 1.7% (1/5
TLR 3.8% (3/78) 5.1% (3/5
TL-CABG 0.0% (0/78) 3.4% (2/5
TL-PTCA 3.8% (3/78) 1.7% (1/5
TVR not involving the target lesion 1.3% (1/78) 3.4% (2/5
TV/non–TL-CABG 0.0% (0/78) 0.0% (0/5
TV/non–TL-PTCA 1.3% (1/78) 3.4% (2/5
TVR 3.8% (3/78) 8.5% (5/5
Target vessel failure 3.8% (3/78) 8.5% (5/5
Stent thrombosis (ARC)
Deﬁnite 0% (0/78) 0% (0/5
Probable 1.3% (1/78) 0% (0/5
Deﬁnite/probable 1.3% (1/78) 0% (0/5IDDM insulin-dependent diabetes mellitus; NIDDM noninsulin-dependent diabetes mellitus; other aboth with and without DM, with both stents demon-
trating similar rates of TVF, TLR, and TVR at 1 year;
) the angiographic and clinical outcomes in patients
oth with and without DM mirrored the overall EN-
EAVOR IV population, without evidence of effect
odification with respect to the assessed end points;
) the incidences of other safety end points, including
eath, MI, and stent thrombosis, were comparable to
ES and PES throughout the follow-up period in
zation (TLR) for ZES- and PES-treated patients with diabetes mellitus (A) and
iations as in Figure 1.
NIDDM
p Value ZES (n  161) PES (n  172) p Value
1.000 8.4% (13/155) 7.9% (13/164) 1.000
0.0% (0/155) 1.2% (2/164) 0.499
0.0% (0/155) 1.2% (2/164) 0.499
1.000 0.6% (1/155) 1.2% (2/164) 1.000
0.0% (0/155) 0.0% (0/164) N/A
1.000 0.6% (1/155) 1.2% (2/164) 1.000
0.431 0.0% (0/155) 0.0% (0/164) N/A
1.000 8.4% (13/155) 6.1% (10/164) 0.518
0.184 0.6% (1/155) 1.2% (2/164) 1.000
0.634 7.7% (12/155) 4.9% (8/164) 0.358
0.577 3.2% (5/155) 4.9% (8/164) 0.575
0.0% (0/155) 1.8% (3/164) 0.248
0.577 3.2% (5/155) 3.7% (6/164) 1.000
0.290 11.0% (17/155) 9.8% (16/164) 0.854
0.290 11.0% (17/155) 11.6% (19/164) 1.000
1.3% (2/155) 0.6% (1/164) 0.613
1.000 0.0% (0/155) 0.0% (0/164)
1.000 1.3% (2/155) 0.6% (1/164) 0.613B
sculari64)
9)
9)
9)
9)
9)
9)
9)
9)
9)
9)
9)
9)
9)
9)
9)
9)
9)
9)breviations as in Tables 1 and 5.
p
e
w
s
y
a
P
b
r
T
a
o
g
t
d
l
g
r
p
p
r
p
v
l
t
c
a
p
t
t
t
c
a
p
s
p
fi
D
h
r
t
o
o
c
p
o
t
(
c
r
2
w
a
c
T
m
l
a
D
h
(
r
b
o
t
i
t
t
p
D
e
a
w
a
i
w
y
l
(
s
n
c
r
P
h
d
4
S
a
s
t
i
a
a
i
i
o
s
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 0 , 2 0 0 9
O C T O B E R 2 0 0 9 : 9 6 7 – 7 6
Kirtane et al.
Diabetic Persons in the Endeavor IV Trial
974atients with and without DM; and 4) the relative safety,
fficacy, and angiographic outcomes of ZES compared
ith PES in patients with DM did not seem to be
ignificantly impacted by insulin-requiring status.
The Endeavor ZES is a DES that employs a phosphor-
lcholine polymer on a cobalt alloy stent to locally deliver the
ntiproliferative agent zotarolimus to the arterial wall during
CI. This stent has been associated with improvements in
oth angiographic and clinical restenosis end points in a
andomized comparison with the Driver cobalt alloy stent (12).
wo subsequent trials have demonstrated that the ZES is
ssociated with greater angiographic late loss compared with
ther DES (13,15). Nonetheless, despite the greater angio-
raphic late loss observed in these trials, clinical follow-up from
hese trials has demonstrated comparable rates of clinically
riven TLR and TVR with ZES.
Some have hypothesized that the higher angiographic
ate loss associated with the ZES has not translated into a
reater frequency of clinical restenosis events due to the
elatively low-risk patient characteristics of the enrolled
atients in these randomized trials. Alternatively, it is
ossible that, in a given population of PCI patients, the
ange of “tolerated late loss” might be wider than initially
roposed and, moreover, is dependent not only on the mean
alue of late loss but also on the relative homogeneity of the
ate loss distribution. One way to test these assumptions is
o assess the performance of the ZES in higher-risk patient
ohorts, such as patients with DM, as was performed in this
nalysis.
Patients with DM represent a considerable proportion of
atients with coronary artery disease undergoing PCI, and
he risk of adverse outcomes—related both to restenosis of
he treated target lesion as well as to areas remote from the
arget lesion—is typically higher in patients with DM
ompared with nondiabetic patients (1–3). In the present
nalysis from the ENDEAVOR IV trial, angiographic
arameters such as in-stent late loss and percent diameter
tenosis were greater for both stents (ZES and PES) among
atients with DM compared with those without DM. This
nding is consistent with prior observations that have found
M to be associated with more aggressive neointimal
yperplastic response to stenting and confirms the greater
estenotic risk of patients with DM, irrespective of stent
ype.
There are limited data regarding the comparative efficacy
f various DES in patients with DM. For example, the
verall pooled experiences from pivotal randomized trials
omparing 2 approved DES with their base BMS in
atients with DM have consisted of 428 patients (from trials
f the CYPHER sirolimus-eluting stent [Cordis Corpora-
ion, Warren, New Jersey] vs. BMS) (5) and 827 patients
from trials of the PES vs. BMS) (16), respectively. The
urrent DM subgroup analysis of the ENDEAVOR IV eandomized trial represents the largest direct comparison of
commercially available DES.
Although mean late loss and percent diameter stenosis
ere greater with ZES compared with PES in the current
nalysis, there were no differences between the 2 stents in
linical restenosis end points, including TLR, TVR,
VF, and MACE in the overall population of DM. This
ight be due in part to limited sample size but is also
ikely due to the relative infrequency of mandatory
ngiographic follow-up that occurred in the EN-
EAVOR IV trial. Mandatory angiographic follow-up
as been estimated to increase relative risk of TLR
largely occurring from the concomitant “oculostenotic
eflex” that occurs after a protocol-mandated angiogram)
y up to 40% in patients treated with DES (17). The low
verall rates of mandatory angiographic follow-up within
he ENDEAVOR IV trial might have resulted in an
ncrease of the clinical margin of “tolerated late loss,”
herefore providing a more clinically relevant estimate of
he relative efficacy of ZES versus PES within the patient
opulation enrolled in the trial.
The use of ZES and PES in patients with and without
M was associated with a similar incidence of clinical safety
nd points as well, including death, MI, stent thrombosis,
nd overall MACE. Although the ENDEAVOR IV study
as not powered to assess these end points, and therefore
subgroup analysis is limited even further in this regard,
t is reassuring that the overall safety profile of both stents
as similar. Follow-up is currently ongoing with up to 5
ears of follow-up and should allow further monitoring of
ong-term safety data, a critical issue with the use of DES
10,18,19).
In addition, insulin requirement did not seem to have a
ignificant impact on the rate of efficacy or safety end points;
or did it impact the relative efficacy and safety of ZES
ompared with PES. These findings parallel those from a
ecent meta-analysis of 5 double-blind, randomized trials of
ES versus BMS, in which IDDM and NIDDM patients
ad similar rates of TLR and TVR, and insulin requirement
id not independently impact death, cardiac death, or MI at
years for either stent type (6).
tudy limitations. As with any subgroup analysis, this
nalysis should be viewed as hypothesis-generating and is
ubject to limited sample size and thereby limited statis-
ical power. Nonetheless, it does represent data in an
mportant and commonly studied subgroup of patients,
nd the 477 patients with DM in this analysis represent
large sample of patients from a single pivotal random-
zed controlled trial. Perhaps more compelling than the
ndividual analyses stratified by DM status is the absence
f any significant interaction between stent type and DM
tatus with respect to the primary study outcomes.
Although the ENDEAVOR IV trial was critical to
stablishing the efficacy and safety of ZES and served as a
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975ivotal trial for commercial approval of ZES, its clinical
eneralizability is limited to the subset of patients with
elatively noncomplex de novo lesions. Because patients with
M frequently have complex coronary lesions and multivessel
isease, further data from more complex patient populations
re needed before either the efficacy or safety data of the ZES
an be translated into these patient populations. Data from the
ngoing E-FIVE (Endeavor Zotarolimus Eluting Coronary
tent) registry (8,000 “all comer” patients treated with ZES)
nd PROTECT (Patient Related OuTcomes With En-
eavor Versus Cypher Stenting) trial (8,800 “all comer”
atients randomized to either ZES or the CYPHER
irolimus-eluting stent) should help to evaluate the per-
ormance of ZES in this regard. Finally, DM is associ-
ted with an ongoing risk of adverse cardiovascular
utcomes, and thus further follow-up data (beyond 1
ear) are needed to adequately characterize the risk of
dverse efficacy and safety end points. In one real-world
egistry of DES use in patients with DM, “late catch-up”
as been observed with PES over a follow-up period to 3
ears (20).
onclusions
n patients with DM in the ENDEAVOR IV trial,
espite greater angiographic late loss with ZES compared
ith PES, the clinical efficacy and safety of ZES and PES
ere similar at 1 year, paralleling the outcomes in
atients without DM (and in the overall trial). Longer-
erm follow-up in this trial and larger randomized trials
ncluding more complex patients are underway to better
efine the role of ZES in these patient and lesion subsets.
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